Skip to main content
Top
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Primary research

MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1

Authors: Tingting Lu, Ying Yang, Ziming Li, Shun Lu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Emerging evidence reveals that microRNAs (miRNAs) play a crucial role in tumor progression, but the underlying mechanism of microRNAs in lung squamous cell cancer (LSCC) remains unclear.

Method

Western-blotting and quantitative real-time PCR (q-PCR) were carried out to detect mRNA and protein expression. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8), colony-forming assay or sphere-forming assay, respectively.

Results

MiR-214-3p was markedly de-regulated in LSCC tissues and was inversely related to the level of Yes-associated protein1 (YAP1), which is the core transcription regulator of the Hippo signaling pathway. Kaplan–Meier survival curves illustrated that patients with high miR-214-3p expression demonstrated more favorable clinical outcomes. MiR-214-3p overexpression (OE) repressed proliferation and cancer stem-like cells (CSCs) properties in vitro and in vivo xenograft mouse model. Mechanistically, luciferase activity assay revealed that miR-214-3p directly targets YAP1 by specifically binding on the 3′ UTR of YAP1.

Conclusion

MiR-214-3p plays a pivotal role in CSCs properties by targeting YAP1, which provides a potential treatment strategy for LSCC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, et al. Global cancer statistics, 2012. Ca A Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, et al. Global cancer statistics, 2012. Ca A Cancer J Clin. 2015;65(2):87–108.CrossRef
2.
go back to reference Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRef
3.
go back to reference Nicoloso MS, et al. MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9(4):293–302.CrossRef Nicoloso MS, et al. MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9(4):293–302.CrossRef
4.
go back to reference Calin GA, et al. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRef Calin GA, et al. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRef
5.
go back to reference Catalanotto C, et al. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712.CrossRef Catalanotto C, et al. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712.CrossRef
6.
go back to reference Kent OA, et al. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–96.CrossRef Kent OA, et al. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188–96.CrossRef
7.
go back to reference Chakraborty C, et al. miRNA-regulated cancer stem cells: understanding the property and the role of miRNA in carcinogenesis. Tumor Biol. 2016;37(10):13039–48.CrossRef Chakraborty C, et al. miRNA-regulated cancer stem cells: understanding the property and the role of miRNA in carcinogenesis. Tumor Biol. 2016;37(10):13039–48.CrossRef
8.
go back to reference Melton C, et al. MicroRNA regulation of embryonic stem cell self-renewal and differentiation. Cell Biol Stem Cells. 2010;695:105–17.CrossRef Melton C, et al. MicroRNA regulation of embryonic stem cell self-renewal and differentiation. Cell Biol Stem Cells. 2010;695:105–17.CrossRef
9.
go back to reference Liu C, et al. MicroRNA regulation of cancer stem cells. Cancer Res. 2011;71(18):5950–4.CrossRef Liu C, et al. MicroRNA regulation of cancer stem cells. Cancer Res. 2011;71(18):5950–4.CrossRef
10.
go back to reference Chaudhary AK, et al. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett. 2017;402:1–8.CrossRef Chaudhary AK, et al. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett. 2017;402:1–8.CrossRef
11.
go back to reference Li B, et al. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene. 2019;707:78–85.CrossRef Li B, et al. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway. Gene. 2019;707:78–85.CrossRef
12.
go back to reference Harvey KF, et al. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114(4):457–67.CrossRef Harvey KF, et al. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell. 2003;114(4):457–67.CrossRef
13.
go back to reference Udan RS, et al. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5(10):914–20.CrossRef Udan RS, et al. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003;5(10):914–20.CrossRef
14.
go back to reference Zhao B, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–71.CrossRef Zhao B, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–71.CrossRef
15.
go back to reference Snijders AM, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005;24(26):4232–42.CrossRef Snijders AM, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005;24(26):4232–42.CrossRef
16.
go back to reference Zhao B, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61.CrossRef Zhao B, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747–61.CrossRef
17.
go back to reference Zhang X, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30(25):2810–22.CrossRef Zhang X, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 2011;30(25):2810–22.CrossRef
18.
go back to reference Rizvi S, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem. 2016;291(15):8031–47.CrossRef Rizvi S, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem. 2016;291(15):8031–47.CrossRef
19.
go back to reference Lu TT, et al. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018;423:36–46.CrossRef Lu TT, et al. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018;423:36–46.CrossRef
21.
go back to reference Liu Y, et al. MiR-214 suppressed ovarian cancer and negatively regulated semaphorin 4D. Tumor Biol. 2016;37(6):8239–48.CrossRef Liu Y, et al. MiR-214 suppressed ovarian cancer and negatively regulated semaphorin 4D. Tumor Biol. 2016;37(6):8239–48.CrossRef
22.
go back to reference Peng RQ, et al. miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. Biochem Biophys Res Commun. 2017;484(3):623–30.CrossRef Peng RQ, et al. miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. Biochem Biophys Res Commun. 2017;484(3):623–30.CrossRef
23.
go back to reference Wang RF, et al. Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res. 2019;38:20.CrossRef Wang RF, et al. Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res. 2019;38:20.CrossRef
24.
go back to reference Chen DL, et al. Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 2014;60(2):598–609.CrossRef Chen DL, et al. Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 2014;60(2):598–609.CrossRef
25.
go back to reference Penna E, et al. microRNA-214 contributes to melanoma tumor progression through suppression of TFAP2C. EMBO J. 2011;30(10):1990–2007.CrossRef Penna E, et al. microRNA-214 contributes to melanoma tumor progression through suppression of TFAP2C. EMBO J. 2011;30(10):1990–2007.CrossRef
26.
go back to reference Long HX, et al. microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). Oncotarget. 2015;6(36):38705–18.CrossRef Long HX, et al. microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). Oncotarget. 2015;6(36):38705–18.CrossRef
27.
go back to reference Wu DD, et al. Long noncoding RNA MIR31HG is activated by SP1 and promotes cell migration and invasion by sponging miR-214 in NSCLC. Gene. 2019;692:223–30.CrossRef Wu DD, et al. Long noncoding RNA MIR31HG is activated by SP1 and promotes cell migration and invasion by sponging miR-214 in NSCLC. Gene. 2019;692:223–30.CrossRef
Metadata
Title
MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1
Authors
Tingting Lu
Ying Yang
Ziming Li
Shun Lu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01506-2

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine